EA202091455A1 - Стабилизированный фармацевтический состав, содержащий эверолимус - Google Patents

Стабилизированный фармацевтический состав, содержащий эверолимус

Info

Publication number
EA202091455A1
EA202091455A1 EA202091455A EA202091455A EA202091455A1 EA 202091455 A1 EA202091455 A1 EA 202091455A1 EA 202091455 A EA202091455 A EA 202091455A EA 202091455 A EA202091455 A EA 202091455A EA 202091455 A1 EA202091455 A1 EA 202091455A1
Authority
EA
Eurasian Patent Office
Prior art keywords
everolimus
pharmaceutical composition
composition containing
granules
stabilized pharmaceutical
Prior art date
Application number
EA202091455A
Other languages
English (en)
Inventor
Киунг Хее Хан
Мин Соо Ким
Шин Юнг Парк
Йонг Лае Лим
Original Assignee
Чонг Кун Данг Фармасьютикал Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чонг Кун Данг Фармасьютикал Корп. filed Critical Чонг Кун Данг Фармасьютикал Корп.
Publication of EA202091455A1 publication Critical patent/EA202091455A1/ru

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41A—FUNCTIONAL FEATURES OR DETAILS COMMON TO BOTH SMALLARMS AND ORDNANCE, e.g. CANNONS; MOUNTINGS FOR SMALLARMS OR ORDNANCE
    • F41A17/00—Safety arrangements, e.g. safeties
    • F41A17/42—Safeties for locking the breech-block or bolt in a safety position
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Настоящее изобретение относится к стабилизированному фармацевтическому составу, содержащему эверолимус. В частности, настоящее изобретение относится к фармацевтическому составу, содержащему гранулы, содержащие эверолимус в качестве активного ингредиента и бутилгидрокситолуол в качестве антиоксиданта. Кроме того, настоящее изобретение относится к способу получения фармацевтического состава, содержащего эверолимус в качестве активного ингредиента и бутилгидрокситолуол в качестве антиоксиданта, включающему стадии: растворения эверолимуса, бутилгидрокситолуола и связующего(их) и получение смеси; получения гранул из смеси и добавления связывающего вещества в гранулы с получением смеси гранул.
EA202091455A 2018-01-12 2019-01-07 Стабилизированный фармацевтический состав, содержащий эверолимус EA202091455A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180004458A KR102051806B1 (ko) 2018-01-12 2018-01-12 에베로리무스를 포함하는 안정화된 약제학적 제제
PCT/KR2019/000204 WO2019139313A1 (en) 2018-01-12 2019-01-07 Stabilized pharmaceutical formulation comprising everolimus

Publications (1)

Publication Number Publication Date
EA202091455A1 true EA202091455A1 (ru) 2020-10-05

Family

ID=67219083

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091455A EA202091455A1 (ru) 2018-01-12 2019-01-07 Стабилизированный фармацевтический состав, содержащий эверолимус

Country Status (7)

Country Link
JP (1) JP7218372B2 (ru)
KR (1) KR102051806B1 (ru)
CN (1) CN111565714B (ru)
BR (1) BR112020014292A2 (ru)
EA (1) EA202091455A1 (ru)
MX (1) MX2020007434A (ru)
WO (1) WO2019139313A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111388455B (zh) * 2020-04-09 2022-09-02 沈阳药科大学 一种依维莫司口腔膜剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
EP2054061A4 (en) * 2006-08-02 2009-09-02 Ariad Pharma Inc COMBINATION THERAPY
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
CA2937492C (en) * 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
ES2663744T3 (es) * 2011-10-06 2018-04-16 Novartis Ag Composiciones farmacéuticas que comprenden 40-O-(2-hidroxi)etil-rapamicina
KR20140032586A (ko) * 2012-09-06 2014-03-17 한국원자력의학원 Ｐｔｅｎ 기능저하에 의한 ｅｇｆｒ-ｔｋｉ 저해제-내성 폐암의 방사선 치료용 약학 조성물
TW201503912A (zh) * 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
MX367121B (es) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Composición sólida estable de inmunosupresores.
KR20150138104A (ko) * 2014-05-30 2015-12-09 동아에스티 주식회사 베포타스틴과 글리세릴베헤네이트를 포함하는 약제학적 제제
CN104398483B (zh) * 2014-11-05 2018-01-26 上海医药集团青岛国风药业股份有限公司 一种奥美沙坦酯片及其制备工艺
CN105106145A (zh) * 2015-08-27 2015-12-02 济川药业集团有限公司 一种依维莫司片剂及其制备方法
US20190022073A1 (en) * 2015-09-03 2019-01-24 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
JP2018111662A (ja) * 2017-01-12 2018-07-19 ニプロ株式会社 エベロリムス製剤

Also Published As

Publication number Publication date
KR102051806B1 (ko) 2019-12-04
BR112020014292A2 (pt) 2020-12-08
WO2019139313A1 (en) 2019-07-18
KR20190086212A (ko) 2019-07-22
JP7218372B2 (ja) 2023-02-06
CN111565714A (zh) 2020-08-21
JP2021510374A (ja) 2021-04-22
MX2020007434A (es) 2022-04-27
CN111565714B (zh) 2022-05-17

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
PH12018502516B1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
EA201891099A1 (ru) 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201790306A1 (ru) 2-(морфолин-4-ил)-1,7-нафтиридины
EA201892734A1 (ru) ПРОИЗВОДНЫЕ АЗАБЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ pI3K BETA
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
MX2018012087A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
EA201792421A1 (ru) Амидозамещенные производные циклогексана
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
EA202090448A1 (ru) Дигидрооксадиазиноны
MX2016012668A (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1.
PH12020550608A1 (en) Pyrrole derivatives as acc inhibitors
MX2021006969A (es) Ligante peptidico.
EP4327880A3 (en) Solid state form of ribociclib succinate
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
AU2017262586A1 (en) Improved drug formulations
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2019008865A (es) Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции